Therapeutic application of pluripotent stem cells: Challenges and risks

Frontiers in Medicine

Volumn 4, Issue DEC, 2017, Pages

  Martin, Ulrich ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cell product; Cellular therapy; Clinical translation; Embryonic stem cells; Good medical practice; Induced pluripotent stem cells; Risks

Indexed keywords

EID: 85060945712     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2017.00229     Document Type: Review

References (47)

1. Jiang M, He B, Zhang Q, Ge H, Zang MH, Han ZH, et al. Randomized controlled trials on the therapeutic effects of adult progenitor cells for myocardial infarction: meta-analysis. Expert Opin Biol Ther (2010) 10(5):667-80. doi:10.1517/14712591003716437
2. Goldstein G, Toren A, Nagler A. Transplantation and other uses of human umbilical cord blood and stem cells. Curr Pharm Des (2007) 13(13):1363-73. doi:10.2174/138161207780618759
3. Rothe M, Modlich U, Schambach A. Biosafety challenges for use of lentiviral vectors in gene therapy. Curr Gene Ther (2013) 13(6):453-68. doi:10.2174/15665232113136660006
4. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 131(5):861-72. doi:10.1016/j.cell.2007.11.019
5. Shi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov (2017) 16(2):115-30. doi:10.1038/nrd.2016.245
6. Haase A, Göhring G, Martin U. Generation of non-transgenic iPS cells from human cord blood CD34+ cells under animal component-free conditions. Stem Cell Res (2017) 21:71-3. doi:10.1016/j.scr.2017.03.022
7. Merkert S, Bednarski C, Göhring G, Cathomen T, Martin U. Generation of a gene-corrected isogenic control iPSC line from cystic fibrosis-patient specific iPSCs homozygous for p.Phe508del mutation mediated by TALENs and ssODN. Stem Cell Res (2017) 23:95-7. doi:10.1016/j.scr.2017.07.010
8. Zweigerdt R, Olmer R, Singh H, Haverich A, Martin U. Scalable expansion of human pluripotent stem cells in suspension culture. Nat Protoc (2011) 6(5):689-700. doi:10.1038/nprot.2011.318
9. Weissbein U, Benvenisty N, Ben-David U. Quality control: genome maintenance in pluripotent stem cells. J Cell Biol (2014) 204(2):153-63. doi:10.1083/jcb.201310135
10. Alper J. Geron gets green light for human trial of ES cell-derived product. Nat Biotechnol (2009) 27(3):213-4. doi:10.1038/nbt0309-213a
11. Cyranoski D. Japanese man is first to receive 'reprogrammed' stem cells from another person. Nature (2017). doi:10.1038/nature.2017.21730
12. Menasche P, Vanneaux V, Hagege A, Bel A, Cholley B, Cacciapuoti I, et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J (2015) 36(30):2011-7. doi:10.1093/eurheartj/ehv189
13. Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet (2015) 385(9967):509-16. doi:10.1016/S0140-6736(14)61376-3
14. Haase A, Olmer R, Schwanke K, Wunderlich S, Merkert S, Hess C, et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell (2009) 5(4):434-41. doi:10.1016/j.stem.2009.08.021
15. Schlaeger TM, Daheron L, Brickler TR, Entwisle S, Chan K, Cianci A, et al. A comparison of non-integrating reprogramming methods. Nat Biotechnol (2015) 33(1):58-63. doi:10.1038/nbt.3070
16. Olmer R, Lange A, Selzer S, Kasper C, Haverich A, Martin U, et al. Suspension culture of human pluripotent stem cells in controlled, stirred bioreactors. Tissue Eng Part C Methods (2012) 18(10):772-84. doi:10.1089/ten.TEC.2011.0717
17. Kropp C, Kempf H, Halloin C, Robles-Diaz D, Franke A, Scheper T, et al. Impact of feeding strategies on the scalable expansion of human pluripotent stem cells in single-use stirred tank bioreactors. Stem Cells Transl Med (2016) 5(10):1289-301. doi:10.5966/sctm.2015-0253
18. Burridge PW, Thompson S, Millrod MA, Weinberg S, Yuan X, Peters A, et al. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One (2011) 6(4):e18293. doi:10.1371/journal.pone.0018293
19. Saxena P, Heng BC, Bai P, Folcher M, Zulewski H, Fussenegger M. A programmable synthetic lineage-control network that differentiates human IPSCs into glucose-sensitive insulin-secreting beta-like cells. Nat Commun (2016) 7:11247. doi:10.1038/ncomms11247
20. Tao Y, Zhang SC. Neural subtype specification from human pluripotent stem cells. Cell Stem Cell (2016) 19(5):573-86. doi:10.1016/j.stem.2016.10.015
21. Lian X, Zhang J, Azarin SM, Zhu K, Hazeltine LB, Bao X, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat Protoc (2013) 8(1):162-75. doi:10.1038/nprot.2012.150
22. Huang SX, Green MD, de Carvalho AT, Mumau M, Chen YW, D'Souza SL, et al. The in vitro generation of lung and airway progenitor cells from human pluripotent stem cells. Nat Protoc (2015) 10(3):413-25. doi:10.1038/nprot.2015.023
23. Kempf H, Olmer R, Haase A, Franke A, Bolesani E, Schwanke K, et al. Bulk cell density and Wnt/TGFbeta signalling regulate mesendodermal patterning of human pluripotent stem cells. Nat Commun (2016) 7:13602. doi:10.1038/ncomms13602
24. Qi Y, Zhang XJ, Renier N, Wu Z, Atkin T, Sun Z, et al. Combined small-molecule inhibition accelerates the derivation of functional cortical neurons from human pluripotent stem cells. Nat Biotechnol (2017) 35(2):154-63. doi:10.1038/nbt.3777
25. Gaj T, Gersbach CA, Barbas CF III. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol (2013) 31(7):397-405. doi:10.1016/j.tibtech.2013.04.004
26. Merkert S, Wunderlich S, Bednarski C, Beier J, Haase A, Dreyer AK, et al. Efficient designer nuclease-based homologous recombination enables direct PCR screening for footprintless targeted human pluripotent stem cells. Stem Cell Reports (2014) 2(1):107-18. doi:10.1016/j.stemcr.2013.12.003
27. Templin C, Zweigerdt R, Schwanke K, Olmer R, Ghadri JR, Emmert MY, et al. Transplantation and tracking of human-induced pluripotent stem cells in a pig model of myocardial infarction: assessment of cell survival, engraftment, and distribution by hybrid single photon emission computed tomography/computed tomography of sodium iodide symporter transgene expression. Circulation (2012) 126(4):430-9. doi:10.1161/CIRCULATIONAHA.111.087684
28. Klug MG, Soonpaa MH, Koh GY, Field LJ. Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts. J Clin Invest (1996) 98(1):216-24. doi:10.1172/JCI118769
29. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 365(18):1673-83. doi:10.1056/NEJMoa1106152
30. Valina C, Pinkernell K, Song YH, Bai X, Sadat S, Campeau RJ, et al. Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction. Eur Heart J (2007) 28(21):2667-77. doi:10.1093/eurheartj/ehm426
31. Shiba Y, Fernandes S, Zhu WZ, Filice D, Muskheli V, Kim J, et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature (2012) 489(7415):322-5. doi:10.1038/nature11317
32. Chong JJ, Yang X, Don CW, Minami E, Liu YW, Weyers JJ, et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature (2014) 510(7504):273-7. doi:10.1038/nature13233
33. Martens A, Rojas SV, Baraki H, Rathert C, Schecker N, Zweigerdt R, et al. Substantial early loss of induced pluripotent stem cells following transplantation in myocardial infarction. Artif Organs (2014) 38(11):978-84. doi:10.1111/aor.12268
34. Ronen D, Benvenisty N. Genomic stability in reprogramming. Curr Opin Genet Dev (2012) 22(5):444-9. doi:10.1016/j.gde.2012.09.003
35. Abyzov A, Mariani J, Palejev D, Zhang Y, Haney MS, Tomasini L, et al. Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells. Nature (2012) 492(7429):438-42. doi:10.1038/nature11629
36. Tomasetti C, Li L, Vogelstein B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science (2017) 355(6331):1330-4. doi:10.1126/science.aaf9011
37. Reardon S, Cyranoski D. Japan stem-cell trial stirs envy. Nature (2014) 513(7518):287-8. doi:10.1038/513287a
38. Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med (2017) 376(11):1038-46. doi:10.1056/NEJMoa1608368
39. Baker M. Stem-cell pioneer bows out. Nature (2011) 479(7374):459. doi:10.1038/479459a
40. Blin G, Nury D, Stefanovic S, Neri T, Guillevic O, Brinon B, et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest (2010) 120(4):1125-39. doi:10.1172/JCI40120
41. Kempf H, Olmer R, Kropp C, Ruckert M, Jara-Avaca M, Robles-Diaz D, et al. Controlling expansion and cardiomyogenic differentiation of human pluripotent stem cells in scalable suspension culture. Stem Cell Reports (2014) 3(6):1132-46. doi:10.1016/j.stemcr.2014.09.017
42. Hattori F, Chen H, Yamashita H, Tohyama S, Satoh YS, Yuasa S, et al. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat Methods (2010) 7(1):61-6. doi:10.1038/nmeth.1403
43. Dubois NC, Craft AM, Sharma P, Elliott DA, Stanley EG, Elefanty AG, et al. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat Biotechnol (2011) 29(11):1011-8. doi:10.1038/nbt.2005
44. Tohyama S, Hattori F, Sano M, Hishiki T, Nagahata Y, Matsuura T, et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell (2013) 12(1):127-37. doi:10.1016/j.stem.2012.09.013
45. Jung JJ, Husse B, Rimmbach C, Krebs S, Stieber J, Steinhoff G, et al. Programming and isolation of highly pure physiologically and pharmacologically functional sinus-nodal bodies from pluripotent stem cells. Stem Cell Reports (2014) 2(5):592-605. doi:10.1016/j.stemcr.2014.03.006
46. Lee JH, Protze SI, Laksman Z, Backx PH, Keller GM. Human pluripotent stem cell-derived atrial and ventricular cardiomyocytes develop from distinct mesoderm populations. Cell Stem Cell (2017) 21(2):179-94.e4. doi:10.1016/j.stem.2017.07.003
47. Gornalusse GG, Hirata RK, Funk SE, Riolobos L, Lopes VS, Manske G, et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol (2017) 35(8):765-72. doi:10.1038/nbt.3860